China issued Order 818 governing the administration of clinical research and clinical translation and application of biomedical new technologies, establishing a pathway intended to accelerate commercialization for cell and gene therapeutics and related advanced modalities. The framework allows eligible treatments to be clinically translated at 3A hospitals without requiring NMPA drug registration, once translational approval is granted. Order 818 also introduces a structured risk observation window described as one to five years, after which technologies can shift from the “tech track” into a drug track. The rules are positioned to standardize the advanced-therapy development environment and potentially speed time to clinical adoption, including hospital-charging permissions after translational approval. Industry stakeholders will now focus on boundary delineation guidance—what technologies fall under Order 818 versus remaining under NMPA registration. International firms partnering with Chinese entities are likely to revisit contract structures and milestones because the regulatory pathway can change development timelines and compliance obligations. For biotech professionals, the practical effect is the possibility of faster clinical translation in China while formal drug registration requirements remain relevant for therapies intended for broad distribution and mass manufacturing.